RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05987826, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. 3)Histology or cytology diagnose of non-small cell lung cancer within 60 days

    Inclusion criterion 3

  3. 8)Without prior anti-tumor treatment

    Inclusion criterion 8

    2)Any prior anti-tumor treatment

    Exclusion criterion 2

  4. 7)EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)

    Inclusion criterion 7

  5. 6)According to RECIST 1.1, patients have at least one measureable tumor lesion (The longest axis ≥10mm)

    Inclusion criterion 6

  6. 3)With history of other malignancy except for radical resected tumors without recurrence for 5 years or more

    Exclusion criterion 3

  7. 11)Women with pregnancy or breastfeeding

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05987826, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1)Provide informed consent prior to any study specific procedures
  • 2)at least 18 years of age,not more than 75 years
  • 3)Histology or cytology diagnose of non-small cell lung cancer within 60 days
  • 4)ECOG PS of 0 to 1 at screening with no clinically significant deterioration in the previous 2 weeks
  • 5)Stage II-IIIB NSCLC that is expected to be resectable, as assessed by the investigator (8 thUICCTNM staging), with stage IIIB only including cT3N2M0 patients
  • 6)According to RECIST 1.1, patients have at least one measureable tumor lesion (The longest axis ≥10mm)
  • 7)EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)
  • 8)Without prior anti-tumor treatment
  • 9) Withe adequate organ function of hematology, liver and kidney
  • 10)Using adequate and effective contraception, Male patients should be use condoms; women should refrain from breastfeeding and have a negative pregnancy test prior to the first administration of the study drug if within during child-bearing age

Exclusion Criteria:

  • 1)Dual or multiple primary NSCLC
  • 2)Any prior anti-tumor treatment
  • 3)With history of other malignancy except for radical resected tumors without recurrence for 5 years or more
  • 4)History of interstitial lung disease or with relative risk factors
  • 5)Diseases or clinical states with severe abnormalities of gastrointestinal function that may interfere with the ingestion, transit, or absorption of the study drug.e.g., inability to take medication orally, uncontrolled nausea and vomiting
  • 6)Use of strong CYP3A4 inhibitors within 7 days or strong CYP3A4 inducers within 21 days before enrolment; use of traditional Chinese medicine with anti-tumor effect within 21 days before enrolment
  • 7)With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active HBV/HCV/HIV or other infections requiring infusion treatment
  • 8)Prolongation of ECG QTc or with relative risk factors
  • 9)psychopath and/or mental illness
  • 10)Pre-existing or coexisting bleeding disorders
  • 11)Women with pregnancy or breastfeeding
  • 12)Allergic to study drugs or any component
  • 13)Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate

Quoted from ClinicalTrials.gov, NCT05987826, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05987826, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05987826